Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. - Wikidata - wikimedia - TriplyDB

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

http://www.wikidata.org/entity/Q35693717

about

Adjuvant radiotherapy following radical prostatectomy for prostate cancer Adjuvant radiotherapy following radical prostatectomy for prostate cancer Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes.Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience.Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.Saudi Oncology Society clinical management guidelines for prostate cancer.Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.Prostate-specific membrane antigen-based therapeutics.Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database.PET Imaging of Prostate Cancer Using C-Acetate.A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy Postoperative radiotherapy after radical prostatectomy: indications and open questions Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report Management of biochemical recurrence after primary localized therapy for prostate cancer Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?Genome abnormalities precede prostate cancer and predict clinical relapse PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma.Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Prognostic value of serum markers for prostate cancer.Salvage radiotherapy after radical prostatectomy: outcomes and prognostic factors especially focusing on pathological findings.

P2860

Q24234347-2B237CE5-5A9F-440C-9786-68179322FF98 Q24242552-F380044A-BA60-4D56-B53A-04360CB1C512 Q24605205-684E5482-2112-41DA-8F55-6C5DF9BB5B6E Q26747782-0D4C0909-A92E-44D3-B355-D6E19CED3BB7 Q26751574-93EA4B12-831A-476E-8E59-7D1164B5C3A2 Q26777128-36220882-24E4-4C39-A8A0-86B67051D06D Q26996477-3508F16C-2449-4FC1-9852-2577884C52A9 Q28541306-56560F50-E5DA-4199-AA2D-2F09D3B16CE7 Q28541950-1B650093-402D-4494-B801-522F151B6F38 Q30405851-A0525C27-962E-43C4-A087-41594856DF2B Q30656223-6B69F3C8-D996-4524-837D-B706A034F8D0 Q33317042-96BE6D97-5A1B-41EC-B9DF-B901586B2D36 Q33645821-D2EA617D-14C0-4B20-9713-BFA3B7DDD6FD Q33710312-D0170985-1FA2-4769-B4D6-BDF62C909C95 Q33759217-19C59861-DC71-4D22-B4B0-51A178AD5647 Q33766462-A9210556-0E64-48DA-919D-B3662334458B Q34062324-898F2A9F-CA8E-403D-AAE5-67455BF9BA41 Q34310143-02097785-8C3F-4DA1-90C9-03B3252B7426 Q34437308-148D4DA8-2CB6-4AC6-AFB1-7F6D00E5A788 Q34725046-D34D77DD-D73D-41C1-991F-4E44A92BABC7 Q34794205-0EC8F67E-9FCC-4E6E-ACA4-FE363D8169A3 Q34997355-C65BBFFC-E2C5-40C0-84E7-0716201E63DF Q35041485-9E963412-BFEE-4DAD-B9A9-51E97502E78A Q35132944-419E40C6-9FFA-4100-870E-A7F60EF0F115 Q35231126-6C2BB7A6-A72A-45EE-A06A-0D5DD1C5A8EA Q35288176-FCA08C3B-F3C9-47DC-AF06-9AAEFDBB5FEE Q35322697-47D2A724-BE7D-4CA0-9E54-EE0BA3B0A9B1 Q35863963-A406B605-E0EC-47CD-93BB-A400067D1D41 Q35924258-3B880F86-4F8E-4350-90DF-CB0486E1EEDD Q35969948-6208592F-6F8D-4789-9FD0-0CD0F8D28549 Q35981941-E8064656-E137-4681-B084-BE26CCFCA66A Q36010923-904A1AF4-29E7-48B8-B0ED-065BBF74F31C Q36042291-E6E4FD46-3B08-400B-93E1-9274C4EA3A75 Q36065143-14B667AC-00D3-4021-85FC-51D2FFA74F2E Q36085426-51C62D12-3DBF-4631-98E3-506256547FB0 Q36108451-F6CF3B7A-91E9-4545-93A5-6EC229DD7781 Q36149384-D4E75CB2-90EC-42D4-9EA0-86E33D9A994E Q36173646-D7F2DF68-FD84-4592-93BC-426CAE28605F Q36194964-D6FBA34F-A552-4323-A639-DE4E4F52C8A6 Q36197823-F791C86F-299D-4AB1-8B57-141A914114AF

P2860

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

http://www.wikidata.org/entity/Q35693717

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@ast

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@en

type

label

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@ast

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@en

prefLabel

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@ast

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@en

P1433

Q35693717-934DBB4C-AF0D-4094-8B7C-160A1620DF1C

P1476

Q35693717-ECDFDBC6-CE60-4FF1-B2E2-B84EE11B57C4

P2093

Q35693717-028B1469-6E86-422D-80F2-86F0FC349BFA

Q35693717-14088C54-0183-4FC1-B262-8040FC304D32

Q35693717-19E2A853-A140-403C-B8F9-95E0F4B09A91

Q35693717-2A3A3DCD-705C-4F88-8063-1BF8B2E095EA

Q35693717-2E218110-A0BD-4E33-9A8A-2A9B118A58C3

Q35693717-347FEB51-5604-4E21-99C5-1AF758CEC2E5

Q35693717-87A5391D-FCED-4BC6-AF61-9B218DBACCBC

Q35693717-8AB1ED74-F3F1-416C-9542-DEDBF12FF0CD

Q35693717-8BB70C4A-1E0A-4688-B801-F6B4E5483B9F

Q35693717-9B6FE1C2-A903-4165-A5DF-7E8DB9277832

P304

Q35693717-83199815-CD85-4F69-8B24-1F608D72696C

P31

Q35693717-7C4F600E-ECD7-4BA2-931F-A28DEAD9D625

P356

Q35693717-31616435-A8C9-4FA1-8180-F29CA1B0D837

P407

Q35693717-EF1F6519-37C7-426D-BCC6-2BA07C4EA2DB

P433

Q35693717-177C866A-E387-4961-8537-AFF3086E0C00

P478

Q35693717-BAE5BF94-1593-47AA-9055-99634A4727FF

P50

Q35693717-F214E66A-6270-489E-A32A-4FD62D058C04

P577

Q35693717-5495BA5F-E9A3-48FC-B4E4-5B367414F3E7

P5875

Q35693717-332F6BA6-7048-4AD7-8E12-24B3D2FDFF23

P698

Q35693717-99E6949F-3410-45A2-971D-D459A3386DBA

P921

Q35693717-8D0C197C-D4EE-457F-87F7-184F4162D38A

P356

JAMA.291.11.1325

P1433

Journal of the American Medical Association

P1476

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

@en

P2093

Andrew J Stephenson

http://www.w3.org/2001/XMLSchema#string

Bin S Teh

http://www.w3.org/2001/XMLSchema#string

Claus G Roehrborn

http://www.w3.org/2001/XMLSchema#string

David A Pistenmaa

http://www.w3.org/2001/XMLSchema#string

E Brian Butler

http://www.w3.org/2001/XMLSchema#string

Eric A Klein

http://www.w3.org/2001/XMLSchema#string

Heather D Pacholke

http://www.w3.org/2001/XMLSchema#string

Kevin M Slawin

http://www.w3.org/2001/XMLSchema#string

Matthew S Katz

http://www.w3.org/2001/XMLSchema#string

Michael W Kattan

http://www.w3.org/2001/XMLSchema#string

P304

1325-1332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.291.11.1325

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P50

Michael J Zelefsky

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8675541

http://www.w3.org/2001/XMLSchema#string

P698

15026399

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy